Tech Company Inital Public Offerings
Oyster Point Pharmaceuticals IPO
Oyster Point Pharmaceuticals was purchased by . Shares became public on 10/30/2019.
Transaction Overview
Company Name
Announced On
10/30/2019
Transaction Type
IPO
Amount
$80,000,000
Proceeds Purpose
We plan to use the net proceeds from this offering to fund the development of OC-01 and OC-02 and prepare for the commercialization of OC-01, including the initial build-out of a specialty sales organization, and to fund general research and development activities, working capital and other general corporate activities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
202 Carnegie Center 109
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Overview
Oyster Point Pharma (Nasdaq: OYST) is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat ocular surface disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Nau
Chief Financial Officer
Daniel Lochner
VP - Bus. Development
John Snisarenko
VP - General Counsel
Jill Andersen
VP - Marketing
Dawn Koffler
VP - Regulatory Affairs
Loni Da Silva
Browse more venture capital transactions:
Prev: 10/30/2019: Kandji venture capital transaction
Next: 10/30/2019: Searchable.ai venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs